Close Menu
    Facebook X (Twitter) Instagram
    Facebook X (Twitter) Instagram
    BusinessNewsAsia.comBusinessNewsAsia.com
    Subscribe
    • Home
    • Top Stories
    • Business
    • Tech
    • Companies
    • Events
    • Announcements
    BusinessNewsAsia.comBusinessNewsAsia.com
    Home » CGSI Reiterates ‘Add’ Rating on Modern Dental (03600.HK) with Raised Target Price of HK$6.88
    HealthCare

    CGSI Reiterates ‘Add’ Rating on Modern Dental (03600.HK) with Raised Target Price of HK$6.88

    Marie JonesBy Marie JonesSeptember 18, 2025Updated:September 26, 2025No Comments2 Mins Read
    Share
    Facebook Twitter LinkedIn Pinterest Email

    HONG KONG, Sep 18, 2025 – (ACN Newswire) – CGSI reiterates the “Add” rating on Modern Dental (03600.HK) with a higher target price of HK$6.88 in a recent report. According to the report, Modern Dental Group’s 1H25 net profit grew 33% yoy to HK$285m, slightly higher than expected due to stronger Europe and Australia operations. CGSI expects Modern Dental to deliver stable revenue growth in FY25 with an improved EBITDA margin of 24.0% (vs. 21.1% in FY24), driven by 1) stronger demand for high quality dental prosthetic products in Europe and Australia, 2) sales volume recovery in the China market due to its better product quality and brand reputation among dentists, and 3) improved production efficiency in Dongguan, Vietnam, US and Thailand factories.

    CGSI believes the acquisition of Hexa Ceram, Thailand’s largest dental laboratory in terms of market share, will diversify the company’s global distribution and sales network with a larger presence in the Southeast Asia (SEA) region, driving revenue growth in FY25-27F. CGSI reiterates Add on Modern Dental as it is believed that the company will further gain global market share in dental prosthetics. CGSI raises the FY25-26F EPS forecasts by 1-2% on new SEA contribution, with a FY25 net profit forecast of HK$545m. The target price rises to HK$6.88, as it rolls over to FY26F and raises EPS forecasts, based on 10x FY26F P/E.

    *Disclaimer: The views given in this article are extracted from relevant research report. For detailed information, please refer to the full report.

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
    Previous ArticleCounterfeit Products Sold Online in Malaysia Threaten Halal Compliance, Consumer Health, and the E-Commerce Sector, Says Muslim Consumers Association (PPIM)
    Next Article InfoComm India 2025 Sets New Benchmark – Delivering a Digital-Forward Future Through High-Value Buyers and Powering High-Impact Engagement and Learning

    Related Posts

    Everest Medicines Receives Shareholding Increase from Substantial Shareholder CBC Group, Global Expansion Expected to Benefit

    May 22, 2026

    Graphene quantum dots show promise in targeting Parkinson’s-related protein clumping

    May 20, 2026

    Substantial Shareholder Wei Fu Increases Shareholding in Everest Medicines Again, Marking His Second Share Purchase in 2026 and Demonstrating Long-term Confidence

    May 15, 2026
    Add A Comment
    Leave A Reply Cancel Reply

    © 2026 BusinessNewsAsia.com
    • About Us
    • Contact Us
    • BusinessNews.ph
    • AsiaPEVC.com
    • PEVCJournal.com
    • Philippines Today

    Type above and press Enter to search. Press Esc to cancel.